IBSA UK&I assumes direct commercial responsibility for ialuril® in UK and Ireland
Transition supports continuity of supply and aligns ialuril® with IBSA’s expanding UK uro-gynaecology portfolio. WATFORD, UNITED KINGDOM, April 9, 2026 /EINPresswire.com/ -- Watford, UK – IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company …